AcuCort AB (publ)
Research AcuCort AB (publ) (ACUC.ST) on Bullrun: market cap SEK 97.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACUC.ST
- ExchangeXSAT
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 97.06M
- Financial periodQ2 2026
- RevenueSEK 1.16M
- Net income-SEK 8.20M
- Free cash flow-SEK 10.78M
- Gross margin233.4%
Valuation Snapshot
latest market cap is SEK 97.06M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | SEK 97.06M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About AcuCort AB (publ)
AcuCort AB (publ), a pharmaceutical company, identifies, develops, and commercializes drugs in Sweden. The company offers Zeqmelit, a dissolving, thin, and small oral film containing the glucocorticoid dexamethasone for the treatment of severe and acute allergic reactions, asthma, croup in children, nausea and vomiting associated with chemotherapy, and patients with COVID-19 with breathing difficulties and require oxygen therapy. AcuCort AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AcuCort AB (publ)'s market cap?
AcuCort AB (publ)'s market capitalization is SEK 97.06M.
What does AcuCort AB (publ) do?
AcuCort AB (publ), a pharmaceutical company, identifies, develops, and commercializes drugs in Sweden. The company offers Zeqmelit, a dissolving, thin, and small oral film containing the glucocorticoid dexamethasone for the treatment of severe and acute allergic reactions, asthma, croup in children, nausea and vomiting associated with chemotherapy, and patients with COVID-19 with breathing difficulties and require oxygen therapy. AcuCort AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.